Literature DB >> 11728342

The IL-7 receptor controls the accessibility of the TCRgamma locus by Stat5 and histone acetylation.

S K Ye1, Y Agata, H C Lee, H Kurooka, T Kitamura, A Shimizu, T Honjo, K Ikuta.   

Abstract

The IL-7 receptor (IL-7R) plays critical roles in expansion and V(D)J recombination during lymphocyte development. Here we demonstrate that cytokine stimulation rapidly recruits Stat5 and transcriptional coactivators to the Jgamma germline promoter and induces histone acetylation, germline transcription, and accessibility in Ba/F3 cells. We also show that histone acetylation of the TCRgamma locus is significantly reduced in IL-7R-deficient thymocytes and that the introduction of active Stat5 restores the histone acetylation and accessibility of the locus. Furthermore, treatment with histone deacetylase inhibitor recovers the histone acetylation and accessibility in IL-7R-deficient thymocytes. Therefore, these results suggest that Stat5 may recruit the transcriptional coactivators to the Jgamma germline promoter and control the accessibility of the TCRgamma locus by histone acetylation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728342     DOI: 10.1016/s1074-7613(01)00230-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  46 in total

1.  Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.

Authors:  Anne Rascle; James A Johnston; Bruno Amati
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

2.  Changes in histone acetylation are associated with differences in accessibility of V(H) gene segments to V-DJ recombination during B-cell ontogeny and development.

Authors:  Kristen Johnson; Cristina Angelin-Duclos; Sinae Park; Kathryn L Calame
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

3.  Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation.

Authors:  Yongzhi Cui; Greg Riedlinger; Keiko Miyoshi; Wei Tang; Cuiling Li; Chu-Xia Deng; Gertraud W Robinson; Lothar Hennighausen
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

4.  Distinct alterations in chromatin organization of the two IGF-I promoters precede growth hormone-induced activation of IGF-I gene transcription.

Authors:  Dennis J Chia; Jennifer J Young; April R Mertens; Peter Rotwein
Journal:  Mol Endocrinol       Date:  2010-02-16

Review 5.  Forging T-Lymphocyte Identity: Intersecting Networks of Transcriptional Control.

Authors:  Ellen V Rothenberg; Jonas Ungerbäck; Ameya Champhekar
Journal:  Adv Immunol       Date:  2015-10-26       Impact factor: 3.543

Review 6.  Progression of regulatory gene expression states in fetal and adult pro-T-cell development.

Authors:  Elizabeth-Sharon David-Fung; Mary A Yui; Marissa Morales; Hua Wang; Tom Taghon; Rochelle A Diamond; Ellen V Rothenberg
Journal:  Immunol Rev       Date:  2006-02       Impact factor: 12.988

Review 7.  Cytokines, Transcription Factors, and the Initiation of T-Cell Development.

Authors:  Hiroyuki Hosokawa; Ellen V Rothenberg
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 8.  Molecular mechanisms that control mouse and human TCR-alphabeta and TCR-gammadelta T cell development.

Authors:  Tom Taghon; Ellen V Rothenberg
Journal:  Semin Immunopathol       Date:  2008-10-17       Impact factor: 9.623

9.  LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression.

Authors:  Ja Eun Kim; Hong Sook Kim; Yong Jae Shin; Chang Seok Lee; Cheolhee Won; Sin Ae Lee; Jung Weon Lee; Youngsoo Kim; Jae Seung Kang; Sang Kyu Ye; Myung Hee Chung
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

Review 10.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.

Authors:  Lothar Hennighausen; Gertraud W Robinson
Journal:  Genes Dev       Date:  2008-03-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.